Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Rutgeerts, P., Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial (2002) Lancet, 359 (9317), pp. 1541-1549. , DOI 10.1016/S0140-6736(02)08512-4
Colombel, J., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R., Schreiber, S., Pollack, P.F., Adalimumab for Maintenance of Clinical Response and Remission in Patients with Crohn's Disease: The CHARM Trial (2007) Gastroenterology, 132 (1), pp. 52-65. , DOI 10.1053/j.gastro.2006.11.041, PII S0016508506025224
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., Thomsen, O.O., Hanauer, S.B., McColm, J., Bloomfield, R., Sandborn, W.J., Maintenance therapy with certolizumab pegol for Crohn's disease (2007) New England Journal of Medicine, 357 (3), pp. 239-250. , http://content.nejm.org/cgi/reprint/357/3/239.pdf, DOI 10.1056/NEJMoa062897
Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., Van Hogezand, R.A., Podolsky, D.K., Van Deventer, S.J.H., Infliximab for the treatment of fistulas in patients with Crohn's disease (1999) New England Journal of Medicine, 340 (18), pp. 1398-1405. , DOI 10.1056/NEJM199905063401804
Lichtenstein, G.R., Yan, S., Bala, M., Blank, M., Sands, B.E., Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease (2005) Gastroenterology, 128 (4), pp. 862-869. , DOI 10.1053/j.gastro.2005.01.048
Feagan, B.G., Panaccione, R., Sandborn, W.J., D'Haens, G.R., Schreiber, S., Rutgeerts, P.J., Loftus Jr., E.V., Mulani, P., Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study (2008) Gastroenterology, 135, pp. 1493-1499
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Rutgeerts, P., Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort (2009) Gut, 58, pp. 492-500
Marting, A., Belaiche, J., Louis, E., Long term safety and efficacy of infliximab in routine practice (2007) Acta Gastroenterol Belg, 10, pp. D45
Targan, S.R., Hanauer, S.B., Van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T., DeWoody, K.L., Rutgeerts, P.J., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (1997) N Engl J Med, 337, pp. 1029-1035. , Crohn's Disease cA2 Study Group
Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., Fedorak, R.N., Lukas, M., Macintosh, D., Panaccione, R., Pollack, P., Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial (2006) Gastroenterology, 130 (2), pp. 323-332. , DOI 10.1053/j.gastro.2005.11.030, PII S0016508505023152
Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D., Bloomfield, R., Schreiber, S., Certolizumab pegol for the treatment of Crohn's disease (2007) N Engl J Med, 357, pp. 228-238. , PRECISE 1 Study Investigators
Kugathasan, S., Saubermann, L.J., Smith, L., Kou, D., Itoh, J., Binion, D.G., Levine, A.D., Fiocchi, C., Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease (2007) Gut, 56 (12), pp. 1696-1705. , DOI 10.1136/gut.2006.116467
Prajapati, D., Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease (2002) Gastroenterology, 122, pp. A777
Lémann, M., Mary, J.Y., Duclos, B., Veyrac, M., Dupas, J.L., Delchier, J.C., Laharie, D., Colombel, J.F., Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial (2006) Gastroenterology, 130, pp. 1054-1061. , Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
Feagan, B.G., McDonald, J., Panaccione, A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease (2008) Gut, 57 (SUPPL. 2), pp. A66
Colombel, J.F., Rutgeerts, P., Reinisch, W., A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (2008) Gut, 57 (SUPPL. 2), pp. A1
Mackey, A.C., Green, L., Liang, L.-C., Dinndorf, P., Avigan, M., Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease (2007) Journal of Pediatric Gastroenterology and Nutrition, 44 (2), pp. 265-267. , DOI 10.1097/MPG.0b013e31802f6424, PII 0000517620070200000019
Toruner, M., Loftus, E., Harmsen, W., Risk factors for opportunistic infections in patients with inflammatory bowel disease (2008) Gastroenterology, 134, pp. 929-936
Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Belaiche, J., A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with - 308 TNF gene polymorphism (2002) Scandinavian Journal of Gastroenterology, 37 (7), pp. 818-824
Louis, E., Boverie, J., Dewit, O., Baert, F., De Vos, M., D'Haens, G., Treatment of small bowel subocclusive Crohn's disease with infliximab: An open pilot study (2007) Acta Gastro-Enterologica Belgica, 70 (1), pp. 15-19
Hyder, S.A., Travis, S.P.L., Jewell, D.P., McC Mortensen, N.J., George, B.D., Fistulating anal Crohn's disease: Results of combined surgical and infliximab treatment (2006) Diseases of the Colon and Rectum, 49 (12), pp. 1837-1841. , DOI 10.1007/s10350-006-0656-5
Vermeire, S., Louis, E., Carbonez, A., Van Assche, G., Noman, M., Belaiche, J., De Vos, M., Rutgeerts, P., Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease (2002) American Journal of Gastroenterology, 97 (9), pp. 2357-2363. , DOI 10.1016/S0002-9270(02)04348-4
Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., De Vos, M., Rutgeerts, P., Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease (2002) American Journal of Gastroenterology, 97 (6), pp. 1458-1462. , DOI 10.1016/S0002-9270(02)04045-5, PII S0002927002040455
Vermeire, S., Louis, E., Rutgeerts, P., De Vos, M., Van Gossum, A., Belaiche, J., Pescatore, P., Hugot, J., NOD2/CARD15 does not influence response to infliximab in Crohn's disease (2002) Gastroenterology, 123 (1), pp. 106-111. , DOI 10.1053/gast.2002.34172
Hlavaty, T., Ferrante, M., Henckaerts, L., Pierik, M., Rutgeerts, P., Vermeire, S., Predictive model for the outcome of infliximab therapy in crohn's disease based on apoptotic pharmacogenetic index and clinical predictors (2007) Inflammatory Bowel Diseases, 13 (4), pp. 372-379. , DOI 10.1002/ibd.20024
Dideberg, V., Theatre, E., Farnir, F., Vermeire, S., Rutgeerts, P., Vos, M.D., Belaiche, J., Bours, V., The TNF/ADAM 17 system: Implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease (2006) Pharmacogenetics and Genomics, 16 (10), pp. 727-734. , DOI 10.1097/01.fpc.0000230117.26581.a4, PII 0121301120061000000005
Louis, E.J., Watier, H.E., Schreiber, S., Hampe, J., Taillard, F., Olson, A., Thorne, N., Colombel, J.-F., Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: A subanalysis of the ACCENT I study (2006) Pharmacogenetics and Genomics, 16 (12), pp. 911-914. , DOI 10.1097/01.fpc.0000230421.12844.fd, PII 0121301120061200000008
Meuwis, M.A., Fillet, M., Lutteri, L., Marée, R., Geurts, P., De Seny, D., Malaise, M., Louis, E., Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study (2008) Clin Biochem, 41, pp. 960-967
Arijs, I., Quintens, R., Van Lommel, L., Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease (2008) Gut, 57 (SUPPL. 2), pp. A39
Löfberg, R., Louis, E., Reinisch, W., Response to adalimumab in bionaive and anti-TNF exposed patients with Crohn's disease: Results of a phase IIIb clinical trial (2008) Gut, 57 (SUPPL. 2), pp. A248
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., Rutgeerts, P., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease (2003) New England Journal of Medicine, 348 (7), pp. 601-608. , DOI 10.1056/NEJMoa020888
Hanauer, S.B., Wagner, C.L., Bala, M., Mayer, L., Travers, S., Diamond, R.H., Olson, A., Rutgeerts, P., Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease (2004) Clinical Gastroenterology and Hepatology, 2 (7), pp. 542-553. , DOI 10.1016/S1542-3565(04)00238-1, PII S1542356504002381
Maser, E.A., Villela, R., Silverberg, M.S., Greenberg, G.R., Association of Trough Serum Infliximab to Clinical Outcome after Scheduled Maintenance Treatment for Crohn's Disease (2006) Clinical Gastroenterology and Hepatology, 4 (10), pp. 1248-1254. , DOI 10.1016/j.cgh.2006.06.025, PII S154235650600677X
Van Assche, G., Magdelaine-Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Rutgeerts, P., Withdrawal of Immunosuppression in Crohn's Disease Treated with Scheduled Infliximab Maintenance: A Randomized Trial (2008) Gastroenterology, 134 (7), pp. 1861-1868. , DOI 10.1053/j.gastro.2008.03.004, PII S0016508508004356
Karmiris, K., Paintaud, G., Degenne, D., Antibodies against adalimumab in Crohn's disease patients who failed infliximab treatment: Correlation with clinical response and trough levels (2008) Gut, 57 (SUPPL. 2), pp. A67
Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., Antoni, C., Feldmann, M., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (1998) Arthritis and Rheumatism, 41 (9), pp. 1552-1563. , DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO
2-W
St.Clair, E.W., Wagner, C.L., Fasanmade, A.A., Wang, B., Schaible, T., Kavanaugh, A., Keystone, E.C., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial (2002) Arthritis and Rheumatism, 46 (6), pp. 1451-1459. , DOI 10.1002/art.10302
Nguyen, G.C., Kaplan, G.G., Harris, M.L., Brant, S.R., A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients (2008) Am J Gastroenterol, 103, pp. 1443-1450
Lichtenstein, G.R., Olson, A., Travers, S., Diamond, R.H., Chen, D.M., Pritchard, M.L., Feagan, B.G., Sandborn, W.J., Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease (2006) American Journal of Gastroenterology, 101 (5), pp. 1030-1038. , DOI 10.1111/j.1572-0241.2006.00463.x
Sandborn, W.J., Hanauer, S., Loftus Jr., E.V., Tremaine, W.J., Kane, S., Cohen, R., Hanson, K., Jeche, R., An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease (2004) American Journal of Gastroenterology, 99 (10), pp. 1984-1989. , DOI 10.1111/j.1572-0241.2004.40462.x
Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Colombel, J.-F., Panaccione, R., D'Haens, G., Pollack, P.F., Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial (2007) Annals of Internal Medicine, 146 (12), pp. 829-838. , http://www.annals.org/cgi/reprint/146/12/829.pdf
Vermeire, S., Abreu, M., D'Haens, G., Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: Open-label induction preliminary results of the welcome study (2008) Gastroenterology, 134 (SUPPL. 1), pp. A-67
Mozziconacci, N., Vermeire, S., Laharie, D., Efficacy of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF (2008) Gastroenterology, 34 (SUPPL. 1), pp. A-663
Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H., Spehlmann, M.E., Sandborn, W.J., Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial (2007) Gastroenterology, 132, pp. 1672-1683. , International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C., Panaccione, R., Rutgeerts, P., Natalizumab induction and maintenance therapy for Crohn's disease (2005) N Engl J Med, 353, pp. 1912-1925. , International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group
Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Clifford, D.B., Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy (2006) New England Journal of Medicine, 354 (9), pp. 924-933. , http://content.nejm.org/cgi/reprint/354/9/924.pdf, DOI 10.1056/NEJMoa054693
